A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs BMS 986165 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms LATTICE
- Sponsors Bristol-Myers Squibb
- 07 Oct 2019 Planned End Date changed from 28 Sep 2021 to 25 Dec 2023.
- 07 Oct 2019 Planned primary completion date changed from 27 Sep 2021 to 26 Dec 2022.
- 02 Aug 2018 New trial record